环磷酰胺联合来氟米特对狼疮性肾炎患者24h尿蛋白及血清β2微球蛋白水平的影响

Abstract
Figure/Table
References (23)
Related Citation (15)

Download: PDF (605 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Cyclophosphamide combined with Leflunomide on 24 h urine protein and serum β2 microglobulin levels in patients with lupus nephritis.Methods A total of 68 patients with lupus nephritis who were admitted to Nanhai District People's Hospital in Foshan City from August 2018 to August 2020 were selected as the research objects,and they were divided into single group(n=34)and combined group(n=34)by random envelope grouping method.The single group was treated with intravenous Cyclophosphamide,and the combined group was treated with Leflunomide orally on the basis of intravenous Cyclophosphamide.The 24 h urine protein and serum β2 microglobulin levels were compared between the two groups before and after treatment.The changes of liver and kidney function indexes were compared between the two groups before and after treatment.The differences of total effective rate and incidence of adverse reactions between the two groups were analyzed.Results Before treatment,there were no significant differences in the 24 h urine protein level and serum β2 microglobulin level between the two groups(P＞0.05).After treatment,the 24 h urinary protein level and serum β2 microglobulin level in combined group were lower than those in single group,the differences were statistically significant(P＜0.05).Before treatment,there were no statistical significances in serum urea nitrogen,serum creatinine,aspartate aminotransferase and alanine aminotransferase levels between the two groups(P＞0.05).After treatment,the levels of serum urea nitrogen,serum creatinine,aspartate aminotransferase and alanine aminotransferase in combined group were lower than those in single group,the differences were statistically significant(P＜0.05).The total effective rate of combined group was higher than that of single group,and the difference was statistically significant(P＜0.05).The total incidence of adverse reactions in combined group was lower than that in single group,and the difference was statistically significant(P＜0.05).Conclusion The combined treatment of Cyclophosphamide and Leflunomide in patients with lupus nephritis can effectively improve 24 h urine protein and serum β2 microglobulin levels,and at the same time improve various indexes of liver and kidney function,which contributes to the overall effective rate of clinical treatment promote.In addition,the adverse reactions are small,the safety is high,and it has certain clinical promotion and application value.

Key words： Serum &beta 2 microglobulin 24 h urine protein Lupus nephritis Cyclophosphamide Leflunomide Treatment efficiency

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUAN Yibiao
	LUO Fuzhang
	LI Yanhua

Cite this article:

GUAN Yibiao,LUO Fuzhang,LI Yanhua. Effect of Cyclophosphamide combined with Leflunomide on 24 h urine protein and serum β2 microglobulin levels in patients with lupus nephritis[J]. 中国当代医药, 2022, 29(10): 10-13转19.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I10/10

[1]	李晓勇，李方晓，李斌.百令胶囊联合来氟米特和泼尼松治疗狼疮性肾炎的临床研究[J].现代药物与临床，2019，34（1）：154-158.
[2]	陈士军，张晓艳，罗田，等.环磷酰胺联合泼尼松治疗对狼疮性肾炎患者免疫功能及血清类风湿因子，C 反应蛋白及白介素-17 水平的影响[J].实用临床医药杂志，2019，23（15）：75-78，82.
[3]	黄集彬.狼疮性肾炎采用来氟米特联合环磷酰胺治疗的疗效观察[J].医药前沿，2019，9（15）：84.
[4]	中华医学会儿科学分会肾脏学组.狼疮性肾炎诊治循证指南（2016）[J].中华儿科杂志，2018，56（2）：88-94.
[5]	李孟建.来氟米特治疗狼疮肾炎患者的临床研究[J].中国临床药理学杂志，2019，35（16）：1735-1738.
[6]	秦鹏.狼疮性肾炎患者经环磷酰胺治疗前后血清LP-a、HCY 水平变化及其与疗效的关系[J].激光生物学报，2018，27（1）：69-74.
[7]	陈慧娜，党勇.泼尼松联合来氟米特治疗狼疮性肾炎的临床疗效及其安全性评价[J].药物评价研究，2018，41（2）：263-266.
[8]	李佳，魏善斋，孙杰，等.来氟米特联合环磷酰胺治疗重症顽固性狼疮肾炎临床研究[J].中国药业，2018，27（17）：57-59.
[9]	李永涛.环磷酰胺对狼疮性肾炎的治疗效果及不良反应率和安全性评价[J].中国急救医学，2018，38（Z1）：102.
[10]	Chen S，Yin Q，Ren S，et al.A comparison of the effectiveness of cyclophosphamide，leflunomide，corticosteroids，or conservative management alone in patients with IgA nephropathy：a retrospective observational study[J].Sci Rep，2018，8（1）：13662.
[11]	Zhang M，Qi C，Zha Y，et al.Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients：a randomized trial[J].Clin Rheumatol，2018，38（3）：859-867.
[12]	马风英，张如峰，包淑贞.来氟米特联合激素治疗系统性红斑狼疮60 例疗效及预后分析[J].陕西医学杂志，2017，46（8）：1124-1126.
[13]	张宗玮，陈铖，王惠明，等.血清β2微球蛋白水平与系统性红斑狼疮疾病活动度及狼疮性肾损害程度的相关性研究[J].中国全科医学，2019，22（17）：2058-2063.
[14]	蒋奕，胡腾，江成巧.艾滋病血清白蛋白、β2微球蛋白和白介素-8 水平与肾功能的关系[J].河北医药，2018，40（20）：3068-3072.
[15]	黄欣萍，谭焕源，邱承高，等.来氟米特与硫唑嘌呤对狼疮性肾炎的疗效及对血清CXCL16 和CysC 水平的影响分析[J].中国医学装备，2018，15（6）：104-107.
[16]	史今.来氟米特联合环磷酰胺与糖皮质激素治疗系统性红斑狼疮肾炎的效果观察[J].中国医药指南，2018，16（8）：150-151.
[17]	于晶，张彦，夏燕杰，等.来氟米特联合厄贝沙坦治疗狼疮性肾炎疗效及对肾功能的影响[J].中国地方病防治杂志，2017，32（2）：224-225.
[18]	Feist E，Drner T，Kuckelkorn U，et al.Proteasome alphatype subunit C9 is a primary target of autoantibodies in sera of patients with myositis and systemic lupus erythematosus[J].J Exp Med，2019，184（4）：1313-1318.
[19]	刘玲，汤艳华，刘炬.环磷酰胺联合糖皮质激素在系统性红斑狼疮的应用效果[J].中国当代医药，2021，28（29）：56-59.
[20]	饶思捷，李云云，关扬婷，等.比较激素联合来氟米特与其他免疫抑制剂治疗特发性膜性肾病的网状meta 分析[J].中国医药科学，2021，11（24）：42-47，145.
[21]	谭静.来氟米特与环磷酰胺治疗狼疮性肾炎的效果比较[J].中国当代医药，2021，28（13）：109-111.
[22]	项红秀.来氟米特与环磷酰胺治疗重症顽固性狼疮肾炎患者临床疗效及对患者抗EBV 壳抗原抗体和CRP 的影响[J].河北医药，2017，39（6）：919-920，923.
[23]	荆萌萌.来氟米特联合环磷酰胺治疗狼疮性肾炎的效果观察[J].中国实用医刊，2019，46（15）：97-99.